by Elena Iemma | Jul 29, 2025 | Blog
Optimize Your Immunogenicity Strategy with Trusted Expert Advice Immunogenicity is a critical factor in biologic drug development, with the potential to determine a therapy’s success or failure. Undesirable immune responses, including the formation of anti-drug...
by Elena Iemma | Mar 25, 2025 | Uncategorized
Optimize Your Immunogenicity Strategy with Trusted Expert Advice Immunogenicity is a critical factor in biologic drug development, with the potential to determine a therapy’s success or failure. Undesirable immune responses, including the formation of anti-drug...
by Elena Iemma | Dec 20, 2023 | News
PROVIDENCE, RI, December 20, 2023 /PRNewswire/ — EpiVax, Inc. (“EpiVax”), an internationally recognized leader in the field of immunogenicity, today announced that Eisai Co. Ltd. (“Eisai”) has licensed EpiVax’s ISPRI toolkit for immunogenicity risk assessment of...
